Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy

Stem Cells

Volumn 28, Issue 12, 2010, Pages 2217-2228

  Kim, Seong Muk ^a   Oh, Ji Hyeon ^a   Park, Soon A ^a   Rhu, Chung Heon ^a   Lim, Jung Yeon ^a   Kim, Dal Soo ^c   Chang, Jong Wook ^c   Oh, Wonil ^c   Jeun, Sin Soo ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c MEDIPOST Co Ltd   (South Korea)

Author keywords

Gene therapy; Glioma; Irradiation; TRAIL; Umbilical cord blood derived mesenchymal stem cells

Indexed keywords

CASPASE; DEATH RECEPTOR 5; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE TARGETING; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IN VIVO STUDY; IRRADIATION; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; THERAPY EFFECT; TUMOR GENE; UMBILICAL CORD BLOOD; UPREGULATION; XENOGRAFT;

ANIMALS; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; COMBINED MODALITY THERAPY; ENZYME ACTIVATION; GAMMA RAYS; GLIOMA; HUMANS; INTERLEUKIN-8; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TROPISM; UMBILICAL CORD; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 78651066526     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.543     Document Type: Article

References (44)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
2. McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-588.
3. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
4. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol 2006;24:1266-1272.
5. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
6. Wagner W, Wein F, Seckinger A et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005;33:1402-1416.
7. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-1301.
8. Rebelatto CK, Aguiar AM, Moretao MP et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood) 2008;233:901-913.
9. Lawler SE, Peruzzi PP, Chiocca EA. Genetic strategies for brain tumor therapy. Cancer Gene Ther 2006;13:225-233.
10. Hamada H, Kobune M, Nakamura K et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005;96:149-156. (Pubitemid 40575915)
11. Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-1164.
12. Hong X, Miller C, Savant-Bhonsale S et al. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 2009;64:1139-1146.
13. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-3318.
14. Miletic H, Fischer Y, Litwak S et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 2007;15:1373-1381.
15. Kim SM, Lim JY, Park SI et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-9623.
16. Sasportas LS, Kasmieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822-4827.
17. Menon LG, Kelly K, Yang HW et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27:2320-2330.
18. Jeong JA, Hong SH, Gang EJ et al. Differential gene expression profiling of human umbilical cord blood-derived mesenchymal stem cells by DNA microarray. Stem Cells 2005;23:584-593.
19. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: A new strategy for immunosuppression? Trends Immunol 2007;28:219-226.
20. Sato H, Kuwashima N, Sakaida T et al. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther 2005;12:757-768.
21. Klopp AH, Spaeth EL, Dembinski JL et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007;67:11687-11695.
22. Zielske SP, Livant DL, Lawrence TS. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 2009;75:843-853.
23. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001;7:1362-1369. (Pubitemid 32708693)
24. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007;25:4505-4506.
25. Mahalingam D, Szegezdi E, Keane M et al. TRAIL receptor signaling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009;35:280-288.
26. Nagane M, Cavenee WK, Shiokawa Y. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg 2007;106:407-416.
27. Fiveash JB, Gillespie GY, Oliver PG et al. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 2008;71:507-516.
28. Yang SE, Ha CW, Jung M et al. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 2004;6:476-486.
29. Kim CY, Jeong M, Mushiake H et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006;13:330-338. (Pubitemid 43223102)
30. Kim DS, Kim JH, Lee JK et al. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev 2009;18:511-519.
31. Ringe J, Strassburg S, Neumann K et al. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 And CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007;101:135-146. (Pubitemid 46652579)
32. Birnbaum T, Roider J, Schankin CJ et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007;83:241-247. (Pubitemid 46952234)
33. Ries C, Egea V, Karow M et al. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: Differential regulation by inflammatory cytokines. Blood 2007;109:4055-4063.
34. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-1780.
35. Li M, Jendrossek V, Belka C. The role of PDGF in radiation oncology. Radiat Oncol 2007;2:5.
36. Shah K, Tang Y, Breakefield X et al. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003;22:6865-6872. (Pubitemid 37386686)
37. Lee J, Hampl M, Albert P et al. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002;4:312-323. (Pubitemid 34755841)
38. Griffith TS, Anderson RD, Davidson BL et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-2894.
39. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-3630.
40. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. The Prostate 2004;61:35-49. (Pubitemid 39095693)
41. Gong B, Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res 2000;60:5754-5760.
42. Marini P, Schmid A, Jendrossek V et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005;5:5.
43. Kosztowski T, Zaidi HA, Quiñones-Hinojosa A. Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther 2009;9:597-612.
44. Chen MF, Lin CT, Chen WC et al. The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Radiat Oncol Biol Phys 2006;66:244-253.